U.S. Breast Cancer Screening and Diagnostic Market

U.S. Breast Cancer Screening and Diagnostic Market Industry Overview

An Introduction to U.S. Breast Cancer Screening and Diagnostic

The U.S. breast cancer screening and diagnostic market was valued at $1,556.6 million in 2024 and is anticipated to reach $2,342.2 million by the end of 2030, at a CAGR of 7.05% during the forecast period 2024-2030. The U.S. breast cancer screening and diagnostic market has been witnessing impressive double-digit growth, largely driven by the introduction of advanced technologies. The shift to digital mammography has been rapid, with digital systems now accounting for approximately 90% of all mammography procedures in the U.S. as of 2021.This transition has been supported by research showing that digital mammography has greater sensitivity, especially for younger women and those with dense breast tissue. Additionally, digital breast tomosynthesis (DBT) has become more common, as studies indicate it detects more cancers than traditional 2D mammography while also lowering false positive rates. For example, a study published in September 2021 titled ‘Comparative Effectiveness of Digital Breast Tomosynthesis and Mammography in Older Women’ found that DBT identified 2.1 more cancers per 1,000 screening mammograms compared to 2D mammography among older women. Moreover, the rising incidence of breast cancer and the increasing number of specialized diagnostic centers in the U.S. have been further propelling U.S. breast cancer screening and diagnostic market growth.

Market Introduction 

The U.S. breast cancer screening and diagnostic market has been experiencing notable growth, driven by advancements in breast imaging technologies. One key innovation is 3-D mammography, or digital breast tomosynthesis, which represents a significant improvement over traditional 2-D mammography. Unlike 2-D images, breast tomosynthesis captures multiple images from different angles to create a detailed, layered view of the breast that radiologists can closely examine. A comprehensive study by researchers at Yale School of Medicine, analyzing over 272,000 breast cancer screenings over 13 years, found that 3-D mammograms identified breast cancer more frequently and at earlier stages than 2-D mammograms. Specifically, the study indicated that 3-D mammography detected 33% of cancers at advanced stages, compared to 44% for 2-D mammography, highlighting a marked improvement in early detection. Similarly, optoacoustic ultrasound, also known as photoacoustic imaging, is an innovative diagnostic tool that combines laser-induced imaging with traditional ultrasound technology. This method has shown significant promise in enhancing the detection and diagnosis of breast cancer, particularly in differentiating between benign and malignant lesions.

Industrial Impact

The U.S. breast cancer screening and diagnostic market, driven by leading companies such as Hologic, GE Healthcare, and Siemens Healthineers AG, has transformed the landscape of breast cancer detection. By leveraging advanced technologies such as 3-D mammography, and optoacoustic ultrasound, these companies provide a diverse range of diagnostic solutions that enhance early detection and improve accuracy in distinguishing between benign and malignant lesions. 

The innovations in the U.S. breast cancer screening market have a significant impact that goes beyond just diagnosing individual cases. Improved screening methods, such as digital breast tomosynthesis (DBT) and advanced MRI, provide important data that inform clinical trials and drug development. This data helps create more effective treatment strategies tailored to the unique characteristics of each patient, which is especially vital in breast cancer, where identifying specific biomarkers can lead to targeted therapies that enhance patient outcomes.

Additionally, incorporating these advanced screening technologies into public health initiatives raises awareness and encourages more people to participate in screening programs. This increase in participation leads to higher rates of early detection and timely intervention, improving individual health and strengthening community health systems by reducing the number of late-stage diagnoses.

As these technologies continue to evolve and regulatory support grows, the influence of the breast cancer screening and diagnostic market in the U.S. becomes even more pronounced. By advancing precision medicine and providing deeper insights into breast cancer, U.S. breast cancer screening and diagnostic market plays a crucial role in transforming healthcare practices and improving patient outcomes across the country.

Market Segmentation of the U.S. breast cancer screening and diagnostic market:

Segmentation 1: by Technology
• Conventional 2D Mammography
• Digital Breast Tomosynthesis
• Contrast-Enhanced Digital Mammography
• Ultrasound 
• MRI Coils 
• Others

Digital Breast Tomosynthesis Segment to Dominate the U.S. Breast Cancer Screening and Diagnostic, Image-Based Market (by Technology)

Based on product, the U.S. breast cancer screening and diagnostic, image-based market was led by the digital breast tomosynthesis segment, which held a 49.93% share in 2023. The rising adoption of digital breast tomosynthesis (DBT) reflects a strong demand for advanced breast cancer screening technologies. DBT is particularly effective in improving detection rates for women with dense breast tissue, making it a vital tool for early diagnosis. This technology helps reduce false-positive results, leading to better patient experiences and outcomes. The growing recognition of DBT's benefits, supported by clinical guidelines and increased patient awareness, drives its integration into standard screening practices, ultimately advancing breast cancer detection and personalized healthcare solutions which in result propelling the growth of U.S. breast cancer screening and diagnostic market.

Recent Developments in the U.S. Breast Cancer Screening and Diagnostic Market

• In August 2024, Izotropic Corporation, a medical device company focused on the commercialization of IzoView, a breast computed tomography (CT) imaging system, announced its pursuit of a regulatory strategy in the U.S. and EU to launch IzoView as a diagnostic device for patients with dense breast tissue, a common variation that increases the risk of developing breast cancer. The company’s updated regulatory approach aims to position IzoView Breast CT for market entry as a diagnostic imaging tool to be used alongside digital breast tomosynthesis (DBT), specifically for patients with dense breast tissue classified as BI-RADS C and D.
• In March 2024, Mammotome introduced the LumiMARK Biopsy Site Marker, a unique tissue marker designed to be distinct from every angle under ultrasound, mammography, and magnetic resonance.
• In November 2023, GE HealthCare launched a new all-in-one artificial intelligence (AI) application platform designed to assist clinicians in breast cancer detection and enhance workflow efficiency MyBreastAI Suite. This initial release includes three AI applications from iCAD, i.e., ProFound AI for DBT, SecondLook for 2D Mammography, and PowerLook Density Assessment. Together, these tools aim to support early detection, improve patient outcomes, and boost operational productivity in radiology departments.
• In February 2023, Neodynamics formed a partnership with Uniphar Group, a global leader in distribution and logistics. This collaboration aims to facilitate the U.S. launch of NeoNavia, their cutting-edge pulse biopsy system.
• In October 2020, FUJIFILM Medical Systems U.S.A., Inc. expanded its partnership with Volpara Solutions, a software company dedicated to preventing advanced-stage breast cancer. This collaboration aims to offer mammography facilities and clinicians enhanced breast imaging solutions that improve image quality, streamline workflow, and accurately assess patients' breast density.

Demand – Drivers, Challenges, and Opportunities in the U.S. breast cancer screening and diagnostic market

Market Drivers in the U.S. breast cancer screening and diagnostic market: 

Growing Incidence of Breast Cancer: The increasing incidence of breast cancer in the U.S. has been a significant factor driving the growth of the breast cancer screening and diagnostic market. According to statistics published by the American Cancer Society in January 2024, there were over 300,000 new cases of breast cancer reported, alongside a continuing prevalence of 3.5 million cases. This trend heightens the demand for early detection technologies, prompting healthcare facilities to invest more in advanced diagnostic tools such as mammography, MRI, and ultrasound. Also, as breast cancer rates rise, the need for early and accurate detection becomes critical, contributing to substantial growth in the U.S. breast cancer screening and diagnostic market. Healthcare providers are thus motivated to enhance their diagnostic capabilities, ensuring better patient outcomes through timely and precise detection.

Market Challenges in the U.S. breast cancer screening and diagnostic market:

Shortage of Imaging Expertise Leading to Underutilization of Breast Cancer Imaging Solutions: Imaging plays a crucial role in ensuring quality cancer care, but it faces significant challenges in both developing and developed countries. Projections from the Association of American Medical Colleges (AAMC) indicate that the U.S. may encounter a physician shortage of between 37,800 and 124,000 by 2034, with radiology alone expected to see a deficit of 10,300 to 35,600 physicians. The AAMC also identifies issues such as physician burnout and an aging workforce as major factors contributing to these shortages. Additionally, research published in July 2023 by the American College of Radiology highlights the effects of these workforce challenges, specifically on radiology. For example, Montana reported the highest attrition rate, with 25.4% of radiologists, i.e., 16 out of 63, leaving the profession. This situation underscores the critical shortage and high turnover rates in radiology, reflecting broader national concerns about physician shortages and the urgent need for effective strategies to address these workforce issues.

Market Opportunities in the U.S. breast cancer screening and diagnostic market:

Utilization of Multi-Modality Imaging for Breast Cancer Screening: The integration of multi-modality imaging in breast cancer screening and diagnosis marks a significant advancement in the field. This approach enhances diagnostic accuracy, aids in precise surgical planning, and facilitates personalized patient care, ultimately leading to better outcomes for those with breast cancer. As technology continues to advance, the role of multi-modality imaging in managing breast cancer is expected to grow, further improving the quality and effectiveness of care. Additionally, the development and incorporation of multimodal diagnostic imaging systems have been driving major improvements in breast cancer screening and diagnosis. These systems combine various imaging techniques, such as mammography, ultrasound, and tomosynthesis, into a single platform, offering a comprehensive evaluation of breast tissue. This holistic approach boosts diagnostic accuracy, especially in challenging cases involving dense breast tissue, and enhances early detection rates.

Analyst’s Thoughts

According to Swati Sood, Principal Analyst, BIS Research, “The U.S. breast cancer screening and diagnostic market is poised for significant growth driven by technological advancements such as digital breast tomosynthesis (DBT) and enhanced MRI, which improve diagnostic accuracy and early detection, particularly in dense breast tissue. The increasing incidence of breast cancer underscores the need for effective screening solutions and public health initiatives to raise awareness. However, challenges such as potential workforce shortages in radiology and the need for personalized treatment options remain critical. As the regulatory landscape evolves, ensuring equitable access to advanced screening methods will improve patient outcomes and sustain U.S. breast cancer screening and diagnostic market momentum.”